Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | OH2 |
Indication/Tumor Type | rectum cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | rectum cancer | predicted - sensitive | OH2 | Case Reports/Case Series | Actionable | In a Phase I/II trial, a patient with CD274 (PD-L1)-positive (TPS=3) metastatic rectal cancer treated with OH2 in a liver metastasis achieved a partial response with reduced size of the injected and non-injected liver lesions 6.89 months after treatment initiation and discontinued treatment but maintained an ongoing response lasting over 11.25 months (PMID: 33837053). | 33837053 |
PubMed Id | Reference Title | Details |
---|---|---|
(33837053) | Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial. | Full reference... |